PEA (Palmitoylethanolamide)
Specifically for Fibromyalgia
0 up • 0 down
Why it works for Fibromyalgia:
PEA is an endogenous fatty-acid amide with anti-inflammatory, mast-cell-stabilising and neuromodulatory effects (via PPAR-α and “entourage” effects on endocannabinoid signalling). Small clinical trials and open-label studies — and some recent randomized work as adjunctive therapy — show promising reductions in pain and fibromyalgia symptom scores. Evidence is not yet definitive or large-scale; discuss with your clinician before starting it. ScienceDirect
Anti-inflammatory / neuroinflammation reduction. PEA down-modulates local inflammatory signalling and helps reduce activation of mast cells and microglia — cells implicated in neuroinflammation thought to contribute to nociplastic pain in fibromyalgia. ScienceDirect
PPAR-α activation (nuclear receptor). PEA is an agonist at peroxisome proliferator-activated receptor alpha (PPAR-α), which suppresses pro-inflammatory gene expression and is linked to analgesic effects. ScienceDirect
“Entourage” / endocannabinoid-related effects. PEA does not strongly bind classic CB1/CB2 receptors, but it raises/augments endocannabinoid signalling and interacts with other receptors (GPR55 etc.), producing analgesia without classical cannabinoid psychoactivity. ScienceDirect
Effects on central & peripheral sensitization. Human experimental work shows PEA improves measures of central sensitization, conditioned pain modulation and pain tolerance — mechanisms highly relevant to fibromyalgia’s amplified pain processing. (Human crossover trial in healthy volunteers used 3×400 mg/day and found improvements in several central/peripheral pain measures.) MDPI
How to use for Fibromyalgia:
Common study doses
- 3 × 400 mg/day (total 1200 mg/day) – used in a randomized double-blind crossover mechanistic study in healthy volunteers (4 weeks) assessing pain modulation. MDPI
- 600 mg twice daily (600 mg b.i.d., total 1200 mg/day) – used in the randomized FM add-on study where PEA (with acetyl-L-carnitine) was added to duloxetine + pregabalin. That study reported PEA 600 mg b.i.d. for 12 weeks after an initial 12-week stabilization period. Clinical and Experimental Rheumatology
- 1200 mg/day (as single total dose or split dosing) — used in open-label FM studies and combination trials (for example, PEA + melatonin trials). MDPI
Formulation / bioavailability
- Micronized or ultramicronized PEA formulations are commonly used to improve oral absorption; several clinical trials and ongoing RCTs specifically study micronized/ultramicronized PEA. If buying PEA look for these formulations if you want to match what was studied. ICHGCP
Typical treatment duration in studies
- Short mechanistic trials: 4 weeks (healthy volunteers). MDPI
- Fibromyalgia clinical trials/open-label studies: 8–24 weeks (some trials reported 12 weeks after randomisation, others followed up to 24 weeks). Improvements are typically measured over weeks to months. Clinical and Experimental Rheumatology
How it’s been used clinically
- Adjunctive therapy: PEA is often trialled in addition to existing treatments (e.g., added to pregabalin + duloxetine) rather than as monotherapy in published FM trials. Clinical and Experimental Rheumatology
Monitoring / expectations
- Expect that benefits (if any) may take multiple weeks; studies monitored pain scores, fibromyalgia impact questionnaires and related measures. If you start PEA, track pain scores, sleep, fatigue and side effects with your clinician. Clinical and Experimental Rheumatology
Scientific Evidence for Fibromyalgia:
Randomized / controlled trials
- Salaffi F. et al., Clinical and Experimental Rheumatology (2023): randomized study adding PEA 600 mg b.i.d. + acetyl-L-carnitine 500 mg b.i.d. to duloxetine + pregabalin in fibromyalgia — reported significant additional improvement vs control. (Full PDF with methods/doses). Clinical and Experimental Rheumatology
Mechanistic randomized trial (human)
- Lang-Illievich K. et al., Nutrients (2022): randomized, double-blind crossover in healthy volunteers using PEA 3×400 mg/day for 4 weeks; showed improvements in peripheral and central pain measures and pain modulation. (Mechanistic but relevant to FM pain physiology.) MDPI
Open-label / observational / combination studies
- MDPI Nutrients open-label study (PEA + melatonin) in fibromyalgia: 1200 mg PEA + 0.2 mg melatonin daily — reported improvements in pain, sleep and quality-of-life measures. (Open-label design.) MDPI
Clinical trial registries / ongoing RCTs
- Registered double-blind RCT on micronized/ultramicronized PEA in fibromyalgia (NCT04488926 / clinical trial registry entry). Shows ongoing clinical interest and formal trials. ICHGCP
Systematic reviews & recent reviews
- Systematic review of PEA supplementation across conditions (PRISMA) — summarises available RCTs, tolerability and heterogeneity of evidence. Useful for overall evidence appraisal. ScienceDirect
- Springer / Pain & Neurology reviews (2024): narrative/systematic reviews discussing decades of PEA research and role in chronic neuropathic and nociplastic pain. SpringerLink
Practical / educational summaries
- WebMD and manufacturer information pages summarise dosing, uses, and safety considerations (good for quick reference but rely on primary literature for details). WebMD
Specific Warnings for Fibromyalgia:
General tolerability: PEA is generally well tolerated in clinical trials; reported side effects are usually mild (dizziness, headache, nausea, dry mouth, sleepiness) and serious adverse events are rare in published studies. Clinical and Experimental Rheumatology
Pregnancy & breastfeeding: Safety data are insufficient. Most clinical guidance suggests avoiding use in pregnancy or breastfeeding unless a clinician specifically recommends it. optipea.com
Renal/hepatic impairment: Manufacturers and reviewers recommend caution (start low, monitor) in patients with significant renal or hepatic disease, since formal studies in these groups are limited. optipea.com
Drug interactions: No consistent, clinically important interactions have been reported in the literature so far, but high-quality interaction studies are lacking. Because fibromyalgia patients commonly take antidepressants, anticonvulsants, etc., discuss combining PEA with your prescribing clinician. The FM RCTs used PEA as an add-on to duloxetine + pregabalin without major interaction signals in those studies, but monitoring remains prudent. Clinical and Experimental Rheumatology
Regulatory / labelling: PEA is often sold as a dietary supplement or “food for special medical purposes” in various jurisdictions — it is not universally approved as a prescription medicine for fibromyalgia. Product quality, dose, and formulation therefore vary between brands; prefer GMP-certified producers and the same micronized formulations used in trials if trying to replicate study conditions. ScienceDirect
General Information (All Ailments)
What It Is
Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide that belongs to the endocannabinoid-like family of compounds. It is synthesized in the body as part of the biological response to inflammation, pain, and cellular stress. Structurally related to the endocannabinoid anandamide, PEA is found in various foods — including egg yolks, soybeans, peanuts, and some meats — and can also be produced endogenously within tissues.
Unlike classic cannabinoids such as THC, PEA does not bind directly to CB1 or CB2 receptors. However, it has similar modulatory effects on inflammation and pain perception. It has been widely studied as a natural analgesic and anti-inflammatory compound, often used in supplement form for chronic pain, neuropathic conditions, and neuroinflammation.
How It Works
PEA acts as a biological modulator, meaning it helps balance inflammatory and pain processes in the body. Its mechanisms of action involve several pathways:
- Activation of PPAR-α (Peroxisome Proliferator-Activated Receptor Alpha): This nuclear receptor regulates the expression of genes involved in inflammation and energy metabolism. When activated by PEA, it reduces the production of pro-inflammatory cytokines and supports cellular homeostasis.
- Indirect Modulation of the Endocannabinoid System: PEA enhances the actions of endocannabinoids such as anandamide by inhibiting the enzyme that breaks them down (FAAH, fatty acid amide hydrolase). This leads to increased natural pain relief and anti-inflammatory signaling.
- Mast Cell Stabilization: Mast cells release histamine and other pro-inflammatory mediators during immune responses. PEA helps limit mast cell activation and degranulation, reducing local inflammation and nerve sensitization.
- Microglial Modulation in the Nervous System: In the brain and spinal cord, PEA modulates microglial cells — the immune cells of the nervous system — helping to reduce neuroinflammation and protect neurons from damage.
Why It’s Important
PEA plays a significant role in supporting homeostatic balance within the body, particularly in the management of chronic inflammation and pain. Its importance lies in several key areas:
- Pain Management: PEA has demonstrated effectiveness in alleviating neuropathic pain, chronic musculoskeletal pain, fibromyalgia, and sciatic nerve pain. Because it targets multiple inflammatory pathways without directly acting on central nervous system receptors, it is generally non-addictive and well-tolerated.
- Neuroprotection: Research suggests PEA may help protect neurons from oxidative stress and inflammatory damage, making it potentially useful in conditions like multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease.
- Immune and Inflammatory Regulation: Its ability to reduce immune cell overactivation makes PEA relevant in allergic reactions, autoimmune conditions, and inflammatory disorders.
- Natural and Endogenous Support: Since PEA is a substance produced by the body itself, supplementing it can restore or boost physiological balance when natural production declines due to chronic stress, illness, or aging.
Considerations
While PEA is generally recognized as safe and well-tolerated, several factors should be considered when using it as a supplement:
- Dosage and Absorption: Typical dosages range from 300 mg to 1200 mg daily, depending on the condition and formulation. Micronized or ultra-micronized PEA forms are preferred for better absorption and bioavailability.
- Safety Profile: PEA has been studied extensively and shows minimal side effects. However, mild gastrointestinal discomfort or fatigue can occasionally occur. It is not known to interact significantly with most medications, though users should consult a healthcare professional before combining it with other anti-inflammatory or pain medications.
- Consistency and Duration: PEA often requires regular use over several weeks before noticeable effects occur. It is not a quick-acting painkiller but rather a modulator of the body’s natural pain and inflammation control systems.
- Clinical Evidence: While growing, the clinical research base still varies in quality. Results are promising but not universally conclusive for all conditions. More large-scale randomized controlled trials are needed.
- Special Populations: Caution is advised for pregnant or breastfeeding women due to limited safety data. Those with serious medical conditions should use PEA under medical supervision.
Helps with these conditions
PEA (Palmitoylethanolamide) is most effective for general wellness support with emerging research . The effectiveness varies by condition based on clinical evidence and user experiences.
Detailed Information by Condition
Fibromyalgia
PEA is an endogenous fatty-acid amide with anti-inflammatory, mast-cell-stabilising and neuromodulatory effects (via PPAR-α and “entourage” effects on...
Nerve Pain (Neuropathy)
Neuro-immune modulation: PEA is an endogenous lipid that primarily activates PPAR-α, dampening pro-inflammatory cytokines, stabilising mast cells, and...
Community Discussion
Share results, tips, and questions about PEA (Palmitoylethanolamide).
Loading discussion...
No comments yet. Be the first to start the conversation!
Discussion for Fibromyalgia
Talk specifically about using PEA (Palmitoylethanolamide) for Fibromyalgia.
Loading discussion...
No comments yet. Be the first to start the conversation!
Remedy Statistics
Helps With These Conditions
Recommended Products
No recommended products added yet.